European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read MoreThe committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read MoreThe results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into
Read MoreDexcom issued disappointing results and guidance, which the company attributed in part to a change in its salesforce. Source link
Read MoreHealth authorities in the southern Indian state of Kerala are on high alert for the latest in a series of
Read More"This election is likely to produce distinct, binary, opposing health policy outcomes depending on who wins," Raymond James analyst Chris
Read MoreThese 10 U.S. states are letting residents down on quality of life, with high crime, environmental problems and lack of
Read MoreHealth-care workers are testing tech and simulating procedures in a $43 million VA facility called SimVET. Source link
Read MoreThe company plans to conduct studies in the second half of the year evaluating multiple doses of the drug. Source
Read MoreNeuralink is gearing up to implant its second human patient, despite hardware challenges with the first patient. Source link
Read More